Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bioextrax AB is a biotechnology company specializing in the development of innovative and sustainable technologies for waste management and resource recovery. Its primary function is to use proprietary microbiological processes to convert organic waste materials into high-value biopolymers and other reusable products. This enterprise impacts various sectors, including agriculture, waste management, and material science, by providing environmentally friendly alternatives to traditional manufacturing processes. The company's industrial biotechnology solutions focus on enhancing the efficiency and cost-effectiveness of transforming underutilized organic residues into valuable bio-based goods. Bioextrax AB's significance in the market lies in its potential to contribute to the circular economy, promoting sustainability by reducing reliance on fossil fuels and decreasing waste. Through strategic collaborations and continual technology advancements, Bioextrax is poised to influence how industries approach material production and waste reduction.
kr 0.22
kr 0.01 (-2.23%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-2356.54% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 47.0% YoY with margins expanding 1049.1pp.
Negative free cash flow of -kr 26M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 863K
▲ +47.0% YoY
Net Income (TTM)
-kr 18M
▼ -2.1% YoY
Op. Margin
-2106.37%
▲ +1049.1pp YoY
ROIC
-59.62%
▼ -0.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 13M
▼ -37.9% YoY
Op. Cash Flow (TTM)
-kr 13M
▼ -38.7% YoY
Net Debt
-kr 4M
Net Cash Position
Cash & Equiv.
kr 4M
3Y CAGR: +24.2%
Continue Research
Bioextrax AB (BIOEX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bioextrax AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Bioextrax AB scores 40 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -2,106.4% operating margin and a -59.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BIOEX.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.